Low CC16 mRNA Expression Levels in Bronchial Epithelial Cells Are Associated with Asthma Severity
- 15 February 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 207 (4) , 438-451
Abstract
Rationale: CC16 is a protein mainly produced by nonciliated bronchial epithelial cells (BECs) that participates in host defense. Reduced CC16 protein concentrations in BAL and serum are associated with asthma susceptibility. Objectives: Few studies have investigated the relationship between CC16 and asthma progression, and none has focused on BECs. In this study, we sought to determine if CC16 mRNA expression levels in BECs are associated with asthma severity. Methods: Association analyses between CC16 mRNA expression levels in BECs (242 asthmatics and 69 control subjects) and asthma-related phenotypes in Severe Asthma Research Program were performed using a generalized linear model. Measurements and Main Results: Low CC16 mRNA expression levels in BECs were significantly associated with asthma susceptibility and asthma severity, high systemic corticosteroids use, high retrospective and prospective asthma exacerbations, and low pulmonary function. Low CC16 mRNA expression levels were significantly associated with high T2 inflammation biomarkers (fractional exhaled nitric oxide and sputum eosinophils). CC16 mRNA expression levels were negatively correlated with expression levels of Th2 genes (IL1RL1, POSTN, SERPINB2, CLCA1, NOS2, and MUC5AC) and positively correlated with expression levels of Th1 and inflammation genes (IL12A and MUC5B). A combination of two nontraditional T2 biomarkers (CC16 and IL-6) revealed four asthma endotypes with different characteristics of T2 inflammation, obesity, and asthma severity. Conclusions: Our findings indicate that low CC16 mRNA expression levels in BECs are associated with asthma susceptibility, severity, and exacerbations, partially through immunomodulation of T2 inflammation. CC16 is a potential nontraditional T2 biomarker for asthma development and progression.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (HL142769)
- National Heart, Lung, and Blood Institute (AI135108)
- National Heart, Lung, and Blood Institute (HL69116)
- National Heart, Lung, and Blood Institute (HL69130)
- National Heart, Lung, and Blood Institute (HL69149)
- National Heart, Lung, and Blood Institute (HL69155)
- National Heart, Lung, and Blood Institute (HL69167)
- National Heart, Lung, and Blood Institute (HL69170)
- National Heart, Lung, and Blood Institute (HL69174)
- National Heart, Lung, and Blood Institute (HL69349)
- National Heart, Lung, and Blood Institute (UL1RR024992)
- National Heart, Lung, and Blood Institute (M01RR018390)
- National Heart, Lung, and Blood Institute (M01RR07122)
- National Heart, Lung, and Blood Institute (M01RR03186)
- National Heart, Lung, and Blood Institute (HL087665)
- National Heart, Lung, and Blood Institute (HL091762)
- National Heart, Lung, and Blood Institute (U10 HL109172)
- National Heart, Lung, and Blood Institute (HL109168)
- National Heart, Lung, and Blood Institute (HL109152)
- National Heart, Lung, and Blood Institute (HL109257)
- National Heart, Lung, and Blood Institute (HL109146)
- National Heart, Lung, and Blood Institute (HL109250)
- National Heart, Lung, and Blood Institute (HL109164)
- National Heart, Lung, and Blood Institute (HL109086)
- National Heart, Lung, and Blood Institute (HL146002)
- National Heart, Lung, and Blood Institute (HL87665)
- National Heart, Lung, and Blood Institute (RC2HL101487)
- National Heart, Lung, and Blood Institute (AI149754)
- National Heart, Lung, and Blood Institute (HL142769)
- National Heart, Lung, and Blood Institute (AI135108)
- National Heart, Lung, and Blood Institute (HL69116)
- National Heart, Lung, and Blood Institute (HL69130)
- National Heart, Lung, and Blood Institute (HL69149)
- National Heart, Lung, and Blood Institute (HL69155)
- National Heart, Lung, and Blood Institute (HL69167)
- National Heart, Lung, and Blood Institute (HL69170)
- National Heart, Lung, and Blood Institute (HL69174)
- National Heart, Lung, and Blood Institute (HL69349)
- National Heart, Lung, and Blood Institute (UL1RR024992)
- National Heart, Lung, and Blood Institute (M01RR018390)
- National Heart, Lung, and Blood Institute (M01RR07122)
- National Heart, Lung, and Blood Institute (M01RR03186)
- National Heart, Lung, and Blood Institute (HL087665)
- National Heart, Lung, and Blood Institute (HL091762)
- National Heart, Lung, and Blood Institute (U10 HL109172)
- National Heart, Lung, and Blood Institute (HL109168)
- National Heart, Lung, and Blood Institute (HL109152)
- National Heart, Lung, and Blood Institute (HL109257)
- National Heart, Lung, and Blood Institute (HL109146)
- National Heart, Lung, and Blood Institute (HL109250)
- National Heart, Lung, and Blood Institute (HL109164)
- National Heart, Lung, and Blood Institute (HL109086)
- National Heart, Lung, and Blood Institute (HL146002)
- National Heart, Lung, and Blood Institute (HL87665)
- National Heart, Lung, and Blood Institute (RC2HL101487)
- National Heart, Lung, and Blood Institute (AI149754)
This publication has 64 references indexed in Scilit:
- Severe Asthma: Lessons Learned from the National Heart, Lung, and Blood Institute Severe Asthma Research ProgramAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research ProgramAmerican Journal of Respiratory and Critical Care Medicine, 2010
- A novel IL-1 family cytokine, IL-33, potently activates human eosinophilsJournal of Allergy and Clinical Immunology, 2008
- Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroidsProceedings of the National Academy of Sciences, 2007
- Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramJournal of Allergy and Clinical Immunology, 2007
- Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breathThorax, 2004
- Flow cytometric characterization of cell populations in bronchoalveolar lavage and bronchial brushings from patients with chronic obstructive pulmonary diseaseCytometry Part B: Clinical Cytometry, 2004
- Clara cell secretory protein: determination of serum levels by an enzyme immunoassay and its importance as an indicator of bronchial asthma in childrenJournal of Pharmaceutical and Biomedical Analysis, 2004
- Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injuryEuropean Respiratory Journal, 1995
- Protein content in bronchoalveolar lavage fluid of patients with asthma and control subjectsJournal of Allergy and Clinical Immunology, 1995